NVCR – NovoCure Limited
NovoCure LimitedNVCR
$10.72Name : NovoCure Limited
Sector : Healthcare
Industry: Medical Devices
Mark. Cap: $1,219,875,968.00
EPSttm : -1.22
NovoCure Limited
$10.72
1.32%$0.14
NVCR — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
8.84
Margin Of Safety %
Put/Call OI Ratio
0.36
EPS Next Q Diff
-0.15
EPS Last/This Y
-0.32
EPS This/Next Y
0.37
Price
10.72
Target Price
25.07
Analyst Recom
1.5
Performance Q
-25.3
Upside
-498.3%
Beta
0.61
Ticker: NVCR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-17 | NVCR | 12.35 | 0.49 | 2.00 | 46503 |
| 2026-03-18 | NVCR | 12.07 | 0.50 | 1.82 | 47562 |
| 2026-03-19 | NVCR | 12.14 | 0.50 | 1.75 | 48182 |
| 2026-03-20 | NVCR | 11.81 | 0.53 | 3.82 | 49196 |
| 2026-03-23 | NVCR | 11.8 | 0.29 | 0.47 | 26100 |
| 2026-03-24 | NVCR | 11.36 | 0.31 | 0.46 | 27438 |
| 2026-03-25 | NVCR | 11.6 | 0.31 | 1.09 | 28565 |
| 2026-03-26 | NVCR | 11.77 | 0.34 | 0.90 | 30241 |
| 2026-03-27 | NVCR | 10.98 | 0.35 | 0.08 | 30672 |
| 2026-03-30 | NVCR | 10.37 | 0.35 | 0.29 | 30892 |
| 2026-03-31 | NVCR | 10.9 | 0.35 | 1.93 | 31034 |
| 2026-04-01 | NVCR | 10.84 | 0.35 | 0.06 | 31264 |
| 2026-04-02 | NVCR | 10.54 | 0.35 | 0.63 | 31356 |
| 2026-04-06 | NVCR | 10.54 | 0.35 | 0.45 | 31426 |
| 2026-04-08 | NVCR | 10.8 | 0.35 | 0.02 | 32037 |
| 2026-04-09 | NVCR | 11 | 0.35 | 1.26 | 32500 |
| 2026-04-13 | NVCR | 10.73 | 0.36 | 0.71 | 33166 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-17 | NVCR | 12.35 | -57.1 | -15.0 | -1.51 |
| 2026-03-18 | NVCR | 12.08 | -57.1 | -12.0 | -1.51 |
| 2026-03-19 | NVCR | 12.14 | -57.1 | -16.4 | -1.51 |
| 2026-03-20 | NVCR | 11.81 | -57.1 | -11.1 | -1.51 |
| 2026-03-23 | NVCR | 11.80 | -57.1 | -15.2 | -1.51 |
| 2026-03-24 | NVCR | 11.36 | -57.1 | -9.3 | -1.51 |
| 2026-03-25 | NVCR | 11.60 | -57.1 | -18.5 | -1.51 |
| 2026-03-26 | NVCR | 11.76 | -57.1 | -17.4 | -1.51 |
| 2026-03-27 | NVCR | 10.99 | -57.1 | -5.0 | -1.51 |
| 2026-03-30 | NVCR | 10.36 | -65.4 | -6.4 | -1.54 |
| 2026-03-31 | NVCR | 10.90 | -65.4 | -23.7 | -1.54 |
| 2026-04-01 | NVCR | 10.84 | -65.4 | -14.3 | -1.54 |
| 2026-04-02 | NVCR | 10.55 | -65.4 | -11.1 | -1.54 |
| 2026-04-06 | NVCR | 10.54 | -65.4 | -15.2 | -1.54 |
| 2026-04-07 | NVCR | 10.36 | -65.4 | -12.6 | -1.54 |
| 2026-04-09 | NVCR | 11.00 | -65.4 | -18.4 | -1.54 |
| 2026-04-10 | NVCR | 10.59 | -65.4 | -9.4 | -1.54 |
| 2026-04-13 | NVCR | 10.72 | -65.4 | -17.4 | -1.54 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-17 | NVCR | -1.33 | 5.24 | 8.91 |
| 2026-03-18 | NVCR | -1.33 | 5.24 | 8.91 |
| 2026-03-19 | NVCR | -1.33 | 5.24 | 8.91 |
| 2026-03-20 | NVCR | -1.33 | 5.24 | 8.91 |
| 2026-03-23 | NVCR | -1.33 | 5.22 | 8.91 |
| 2026-03-24 | NVCR | -1.33 | 5.22 | 8.91 |
| 2026-03-25 | NVCR | -1.33 | 5.22 | 8.32 |
| 2026-03-26 | NVCR | -1.33 | 5.22 | 8.32 |
| 2026-03-27 | NVCR | -1.33 | 5.22 | 8.32 |
| 2026-03-30 | NVCR | -1.33 | 5.22 | 8.32 |
| 2026-03-31 | NVCR | -1.33 | 5.22 | 8.32 |
| 2026-04-01 | NVCR | -1.33 | 5.22 | 8.32 |
| 2026-04-02 | NVCR | -1.33 | 5.22 | 8.32 |
| 2026-04-06 | NVCR | -1.33 | 5.23 | 8.32 |
| 2026-04-07 | NVCR | -1.33 | 5.23 | 8.32 |
| 2026-04-08 | NVCR | -1.33 | 5.23 | 8.32 |
| 2026-04-09 | NVCR | -1.33 | 5.23 | 8.32 |
| 2026-04-10 | NVCR | -1.33 | 5.23 | 8.32 |
| 2026-04-13 | NVCR | -1.33 | 5.21 | 8.84 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.22
Avg. EPS Est. Current Quarter
-0.51
Avg. EPS Est. Next Quarter
-0.37
Insider Transactions
-1.33
Institutional Transactions
5.21
Beta
0.61
Average Sales Estimate Current Quarter
167
Average Sales Estimate Next Quarter
170
Fair Value
Quality Score
45
Growth Score
40
Sentiment Score
19
Actual DrawDown %
95.4
Max Drawdown 5-Year %
-95.6
Target Price
25.07
P/E
Forward P/E
PEG
P/S
1.86
P/B
3.54
P/Free Cash Flow
EPS
-1.22
Average EPS Est. Cur. Y
-1.54
EPS Next Y. (Est.)
-1.17
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-20.79
Relative Volume
0.41
Return on Equity vs Sector %
-67.3
Return on Equity vs Industry %
-51.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
-17.4
◆
NVCR
Healthcare
$10.72
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
42.4
Range 1M
22.2%
Sup Dist
3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-25.9%
EPS NY
24.1%
52W%
8.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+133.9% upside
Upside
+133.9%
Quality
45
NovoCure LimitedSector: Healthcare
Industry: Medical Devices
Employees: 1605
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR
Latest News
—
Caricamento notizie per NVCR…
stock quote shares NVCR – NovoCure Limited Stock Price stock today
news today NVCR – NovoCure Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch NVCR – NovoCure Limited yahoo finance google finance
stock history NVCR – NovoCure Limited invest stock market
stock prices NVCR premarket after hours
ticker NVCR fair value insiders trading